Clinical trial
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate…
NCT00450008 · The Methodist Hospital Research Institute, Other · Terminated
Key facts
| NCT number | NCT00450008 |
|---|---|
| Title | Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer |
| Official title | Phase II Study of Patients With Hormone-Naïve Prostate Cancer With a Rising Prostate Specific Antigen: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Thalidomide Plus Docetaxel |
| Lead sponsor | The Methodist Hospital Research Institute, Other |
| Collaborators | Bayer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | GM-CSF, thalidomide, docetaxel |
| Enrollment | 9 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Mar 21, 2007 |
| Last update posted | Mar 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: